<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Progesterone for acute traumatic brain injury - Ma, J - 2016 | Cochrane Library</title> <meta content="Progesterone for acute traumatic brain injury - Ma, J - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008409.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Progesterone for acute traumatic brain injury - Ma, J - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008409.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008409.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Progesterone for acute traumatic brain injury" name="citation_title"/> <meta content="Junpeng Ma" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Siqing Huang" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="huangsiqing028@163.com" name="citation_author_email"/> <meta content="Shu Qin" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Chao You" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Yunhui Zeng" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD008409.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/12/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008409.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008409.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008409.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Brain Injuries [*drug therapy, *mortality]; Disability Evaluation; Glasgow Coma Scale; Injury Severity Score; Intracranial Pressure [drug effects]; Neuroprotective Agents [adverse effects, *therapeutic use]; Progesterone [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Risk" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008409.pub4&amp;doi=10.1002/14651858.CD008409.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008409\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008409\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008409.pub4",title:"Progesterone for acute traumatic brain injury",firstPublishedDate:"Dec 22, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Injuries Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008409.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008409.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008409.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008409.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008409.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008409.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008409.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008409.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008409.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008409.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2813 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008409.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/appendices#CD008409-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/table_n/CD008409StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/table_n/CD008409StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Progesterone for acute traumatic brain injury</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information#CD008409-cr-0002">Junpeng Ma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information#CD008409-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Siqing Huang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information#CD008409-cr-0004">Shu Qin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information#CD008409-cr-0005">Chao You</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information#CD008409-cr-0006">Yunhui Zeng</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information/en#CD008409-sec-0095">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 December 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008409.pub4">https://doi.org/10.1002/14651858.CD008409.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008409-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008409-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008409-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008409-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008409-abs-0001" lang="en"> <section id="CD008409-sec-0001"> <h3 class="title" id="CD008409-sec-0001">Background</h3> <p>Traumatic brain injury (TBI) is a leading cause of death and disability, and the identification of effective, inexpensive and widely practicable treatments for brain injury is of great public health importance worldwide. Progesterone is a naturally produced hormone that has well‐defined pharmacokinetics, is widely available, inexpensive, and has steroidal, neuroactive and neurosteroidal actions in the central nervous system. It is, therefore, a potential candidate for treating TBI patients. However, uncertainty exists regarding the efficacy of this treatment. This is an update of our previous review of the same title, published in 2012. </p> </section> <section id="CD008409-sec-0002"> <h3 class="title" id="CD008409-sec-0002">Objectives</h3> <p>To assess the effects of progesterone on neurologic outcome, mortality and disability in patients with acute TBI. To assess the safety of progesterone in patients with acute TBI. </p> </section> <section id="CD008409-sec-0003"> <h3 class="title" id="CD008409-sec-0003">Search methods</h3> <p>We updated our searches of the following databases: the Cochrane Injuries Group's Specialised Register (30 September 2016), the Cochrane Central Register of Controlled Trials (CENTRAL; Issue 9, 2016), MEDLINE (Ovid; 1950 to 30 September 2016), Embase (Ovid; 1980 to 30 September 2016), Web of Science Core Collection: Conference Proceedings Citation Index‐Science (CPCI‐S; 1990 to 30 September 2016); and trials registries: Clinicaltrials.gov (30 September 2016) and the World Health Organization (WHO) International Clinical Trials Registry Platform (30 September 2016). </p> </section> <section id="CD008409-sec-0004"> <h3 class="title" id="CD008409-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of progesterone versus no progesterone (or placebo) for the treatment of people with acute TBI. </p> </section> <section id="CD008409-sec-0005"> <h3 class="title" id="CD008409-sec-0005">Data collection and analysis</h3> <p>Two review authors screened search results independently to identify potentially relevant studies for inclusion. Independently, two review authors selected trials that met the inclusion criteria from the results of the screened searches, with no disagreement. </p> </section> <section id="CD008409-sec-0006"> <h3 class="title" id="CD008409-sec-0006">Main results</h3> <p>We included five RCTs in the review, with a total of 2392 participants. We assessed one trial to be at low risk of bias; two at unclear risk of bias (in one multicentred trial the possibility of centre effects was unclear, whilst the other trial was stopped early), and two at high risk of bias, due to issues with blinding and selective reporting of outcome data. </p> <p>All included studies reported the effects of progesterone on mortality and disability. Low quality evidence revealed no evidence of a difference in overall mortality between the progesterone group and placebo group (RR 0.91, 95% CI 0.65 to 1.28, I² = 62%; 5 studies, 2392 participants, 2376 pooled for analysis). Using the GRADE criteria, we assessed the quality of the evidence as low, due to the substantial inconsistency across studies. </p> <p>There was also no evidence of a difference in disability (unfavourable outcomes as assessed by the Glasgow Outcome Score) between the progesterone group and placebo group (RR 0.98, 95% CI 0.89 to 1.06, I² = 37%; 4 studies; 2336 participants, 2260 pooled for analysis). We assessed the quality of this evidence to be moderate, due to inconsistency across studies. </p> <p>Data were not available for meta‐analysis for the outcomes of mean intracranial pressure, blood pressure, body temperature or adverse events. However, data from three studies showed no difference in mean intracranial pressure between the groups. Data from another study showed no evidence of a difference in blood pressure or body temperature between the progesterone and placebo groups, although there was evidence that intravenous progesterone infusion increased the frequency of phlebitis (882 participants). There was no evidence of a difference in the rate of other adverse events between progesterone treatment and placebo in the other three studies that reported on adverse events. </p> </section> <section id="CD008409-sec-0007"> <h3 class="title" id="CD008409-sec-0007">Authors' conclusions</h3> <p>This updated review did not find evidence that progesterone could reduce mortality or disability in patients with TBI. However, concerns regarding inconsistency (heterogeneity among participants and the intervention used) across included studies reduce our confidence in these results. </p> <p>There is no evidence from the available data that progesterone therapy results in more adverse events than placebo, aside from evidence from a single study of an increase in phlebitis (in the case of intravascular progesterone). </p> <p>There were not enough data on the effects of progesterone therapy for our other outcomes of interest (intracranial pressure, blood pressure, body temperature) for us to be able to draw firm conclusions. </p> <p>Future trials would benefit from a more precise classification of TBI and attempts to optimise progesterone dosage and scheduling. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008409-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008409-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008409-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008409-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008409-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008409-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008409-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008409-abs-0003" lang="en"> <h3>Progesterone for traumatic brain injury</h3> <p><b>Review question</b> </p> <p>To find out whether using the hormone progesterone to treat people who have had an injury to the head that caused brain damage (traumatic brain injury (TBI)) is helpful and safe, if given within 24 hours of the injury. </p> <p><b>Background</b> </p> <p>TBI is one of the main causes of death and disability in people with injuries. Damage to the brain can start at the time of the injury, but can continue for days after the injury too. Progesterone is a hormone that some doctors think could be used as a potential medicine for reducing brain damage if given shortly after TBI. However, as there is uncertainty about the effectiveness of this hormone, it is important that we assess the evidence. </p> <p><b>Study characteristics</b> </p> <p>We searched the medical literature widely for randomised controlled trials that investigated the effects of progesterone in people with TBI up to 30 September 2016. Randomised controlled trials provide the most robust medical evidence. . </p> <p><b>Key results</b> <br/> We included five studies with a total of 2392 participants, and identified three ongoing studies. The studies all compared a group of participants who received progesterone within 24 hours of TBI against a group who received a pretend ‐ or dummy ‐ medicine (known as a placebo) that looked the same as the progesterone. </p> <p>The results of our review did not find evidence that, when compared to placebo, progesterone could reduce death and disability in people with TBI. There were too few data available on the other outcomes that we were interested in (pressure inside the skull (intracranial pressure), blood pressure, body temperature and adverse events (harms)), for us to be able to analyse these in detail. However, although the information available shows no evidence of a difference in effect between the progesterone and control groups for intracranial pressure, blood pressure or body temperature, one study showed an increased level of an adverse event called phlebitis (inflammation in the vein) in the progesterone group, possibly because the progestreone was given into the vein through an intravascular infusion ('drip'). </p> <p><b>Quality of the evidence</b> </p> <p>We judged the quality of the evidence to be low for the data on risk of death, and moderate for the data on risk of disability. These judgements resulted from differences across studies, including different doses of progesterone and different time points for assessment of participants in the included studies. This means that we have limited confidence in the conclusions of this review. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008409-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008409-sec-0081"></div> <h3 class="title" id="CD008409-sec-0082">Implications for practice</h3> <section id="CD008409-sec-0082"> <p>The results of our updated systematic review did not find evidence that the use of progesterone therapy, started within 24 hours of injury, could reduce mortality or disability in people with traumatic brain injury (TBI). However, our confidence in these findings is limited, as the quality of the evidence for these outcomes is of low and moderate, respectively. </p> <p>We are unable to draw firm conclusions about the effects of progesterone therapy on intracranial pressure, blood pressure or body temperature, as the results do not indicate any evidence of an effect. </p> <p>At the moment there is no evidence that progesterone therapy is less safe than placebo for people with TBI, apart from a possible increase in phlebitis in the case of intravascular progesterone. </p> </section> <h3 class="title" id="CD008409-sec-0083">Implications for research</h3> <section id="CD008409-sec-0083"> <p>Although some of the trials included in this review were well conducted in terms of sample size and minimising bias, their utility for determining the effects of progesterone therapy for acute TBI was limited by the heterogeneity of the populations, inconsistency of the interventions and limitations of the outcomes measured. Future trials would benefit from the following. </p> <section id="CD008409-sec-0084"> <h5 class="title">Population</h5> <p>TBI is a complex and heterogeneous condition, so precise characterisation ‐ based, for example, on biomarkers, clinical characteristics and imaging findings‐ is essential before further clinical trials are conducted. This way, more meaningful subgroup analyses can be conducted for TBI trials. </p> </section> <section id="CD008409-sec-0085"> <h5 class="title">Intervention</h5> <p>Future trials should attempt to optimise progesterone dose and schedule. Allometric scaling could determine the most effective dose for humans based on the existing preclinical animal research. </p> </section> <section id="CD008409-sec-0086"> <h5 class="title">Outcomes</h5> <p> <ul id="CD008409-list-0006"> <li> <p>There have been many criticisms of the subjectivity of the Glasgow Outcome Scale (GOS) and its extended version (GOS‐E) for measuring deficits or recovery from TBI. These scales rely on self‐assessment or assessment of a care‐giver, rather than quantifiable measurements of disability. It is possible that more quantitative outcome measures would be beneficial, although these may be more expensive and time‐consuming to implement. </p> </li> <li> <p>In response to criticism of the lack of sensitivity of the GOS, use of multi‐faceted testing approaches to capture more of the relevant clinical information have been proposed. </p> </li> <li> <p>At the very least, analysis methods for the GOS‐E that use more complex forms of statistical evaluation should be introduced to improve prediction of functional outcomes (<a href="./references#CD008409-bbs2-0015" title="AlaliAS , VavrekD , BarberJ , DikmenS , NathensAB , TemkinNR . Comparative study of outcome measures and analysis methods for traumatic brain injury trials. Journal of Neurotrauma2015;32:581–9. ">Alali 2015</a>). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008409-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008409-sec-0015"></div> <div class="table" id="CD008409-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with no progesterone or placebo for traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acute TBI secondary to head injury </p> <p><b>Settings:</b> hospitals, intensive care units </p> <p><b>Intervention:</b> progesterone therapy </p> <p><b>Comparison:</b> no progesterone or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality at end of scheduled follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>175 per 1000</b> </p> <p><b>(125 to 246)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> (0.65 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2376<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is no evidence of a reduction of mortality at the end of scheduled follow‐up as a result of progesterone therapy. Our confidence in this evidence is limited as we have assessed it as low quality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disability (unfavourable outcomes: death, vegetative state, severe disability; GOS 1‐3) at end of scheduled follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>533 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>522 per 1000</b> </p> <p><b>(474 to 565)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.98</b> (0.89 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2260</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no evidence of a difference in disability (unfavourable outcomes) at the end of scheduled follow‐up as a result of progesterone therapy. Our confidence in this evidence is somewhat limited as we have assessed it as moderate quality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intracranial pressure (ICP) within the treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, ICP data were presented as mean values. In <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, ICP data were presented as the mean frequency of pressures exceeding threshold values. In <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>, ICP data were presented as the population with increased ICP. We were therefore not able to perform meta‐analysis. There was no evidence that progesterone therapy has an effect on ICP. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood pressure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Throughout the three‐day infusion interval, there was no difference between the progesterone and placebo groups" (<a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body temperature</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Progesterone group experienced a lower increase in mean temperature than the control group" (<a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> reported that phlebitis or thrombophlebitis was significantly more frequent in the progesterone group than in the placebo group (882 cases, RR 3.03; 95% CI, 1.96 to 4.66). The rates of other serious and non‐serious adverse events were similar in the 4 studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval;<b>GOS:</b> Glasgow Outcome Scale; <b>ICP:</b> intracranial pressure; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We judged the overall risk of bias of two studies as high, and two studies as unclear. However, most data were from studies at low or unclear risk of bias, so we did <i>not</i> downgrade for risk of bias. </p> <p>2. Downgraded once for inconsistency (substantial heterogeneity: I² = 62%, P value 0.03) </p> <p>3. Downgraded once for inconsistency (the dosage, treatment routine and vehicles of progesterone varied across studies. Different time points were involved in the analysis of mortality and unfavourable outcomes). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008409-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008409-sec-0016"></div> <section id="CD008409-sec-0017"> <h3 class="title" id="CD008409-sec-0017">Description of the condition</h3> <p>Traumatic brain injury (TBI) is one of the main causes of death and disability in people with injuries (<a href="./references#CD008409-bbs2-0023" title="GhajarJ . Traumatic brain injury. Lancet2000;356:923‐9. ">Ghajar 2000</a>). Globally, at least 10 million people are killed or hospitalised every year because of TBI (<a href="./references#CD008409-bbs2-0031" title="HyderAA , WunderlichCA , PuvanachandraP , GururajG , KobusingyeOC . The impact of traumatic brain injuries: a global perspective. NeuroRehabilitation2007;22:341‐53. ">Hyder 2007</a>). The cost to society of TBI is considerable. In the USA, it is estimated that the cost of acute treatment and rehabilitation for patients with brain injury is around two billion dollars (USD) per year (<a href="./references#CD008409-bbs2-0035" title="McGarryLJ , ThompsonD . Outcomes and costs of acute treatment of traumatic brain injury. Journal of Trauma2002;53(6):1152‐9. ">McGarry 2002</a>), not including indirect costs to families and society. The identification of effective, inexpensive and widely practicable treatments for brain injury is of great public health importance. </p> <p>Although much of the neurological damage after TBI is caused at the time of the injury, secondary brain damage caused by mechanisms such as brain oedema, free radical formation or release of inflammatory mediators may exacerbate the primary injury. Severe injury sets in motion a cascade of events over several hours that can lead to secondary damage or death of brain tissue. To date, no pharmacologic agent has been shown to improve outcomes of TBI (<a href="./references#CD008409-bbs2-0026" title="GultekinR , HuangS , ClavisiO , PattuwageL , KönigTC , GruenR . Pharmacological interventions in traumatic brain injury: can we rely on systematic reviews for evidence?. Injury2016;47:516‐24. ">Gultekin 2016</a>). Methylprednisolone, once considered a mainstay of treatment, has been shown to be harmful (<a href="./references#CD008409-bbs2-0016" title="AldersonP , RobertsI . Corticosteroids for acute traumatic brain injury. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD000196.pub2] ">Alderson 2008</a>), and there is no evidence to support the use of magnesium in patients with acute TBI (<a href="./references#CD008409-bbs2-0018" title="ArangoMF , BainbridgeD . Magnesium for acute traumatic brain injury. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005400.pub3] ">Arango 2008</a>). It is important to search for safe and clinically effective neuroprotective drugs to prevent secondary brain damage after TBI, and progesterone has several features that make it an attractive candidate. </p> </section> <section id="CD008409-sec-0018"> <h3 class="title" id="CD008409-sec-0018">Description of the intervention</h3> <p>Progesterone, a hormone which is both widely available and inexpensive, has steroidal, neuroactive and neurosteroidal actions in the central nervous system. The pharmacokinetics of progesterone are well known, as the drug has been safely used for a long time (<a href="./references#CD008409-bbs2-0017" title="AllolioB , OremusM , ReinckeM , SchaefferHJ , WinkelmannW , HeckG , et al. High‐dose progesterone infusion in healthy males: evidence against antiglucocorticoid activity of progesterone. European Journal of Endocrinology1995;133:696‐700. ">Allolio 1995</a>; <a href="./references#CD008409-bbs2-0024" title="GoldfienA . The gonadal hormones and inhibitors. Basic and Clinical Pharmacology. 4th Edition. Norwalk, CT: Appleton and Lange: Katzung BG, 1989:493‐516. ">Goldfien 1989</a>). Progesterone is present in the brains of men and women in small, roughly equal concentrations. Progesterone receptors are widely distributed throughout the central nervous system (<a href="./references#CD008409-bbs2-0042" title="SchumacherM , BaulieuEE . Neurosteroids: synthesis and functions in the central and peripheral nervous systems. Ciba Foundation Symposium1995;191:90‐106. ">Schumacher 1995</a>). Although progesterone's non‐neurologic effects are well known, the steroid also has neuroprotective properties (<a href="./references#CD008409-bbs2-0043" title="SinghM , SuC . Progesterone and neuroprotection. Hormones and Behavior2013;63:284‐90. ">Singh 2013</a>). At the preclinical level, there is increasing evidence that progesterone could produce beneficial effects in brain and spinal cord injuries (<a href="./references#CD008409-bbs2-0019" title="BrotfainE , GruenbaumSE , BoykoM , KutzR , ZlotnikA , KleinM . Neuroprotection by estrogen and progesterone in traumatic brain injury and spinal cord injury. Current Neuropharmacology2016;14:641‐53. ">Brotfain 2016</a>), stroke (<a href="./references#CD008409-bbs2-0051" title="YousufS , AtifF , SayeedI , WangJ , SteinDG . Neuroprotection by progesterone after transient cerebral ischemia in stroke‐prone spontaneously hypertensive rats. Hormones and Behavior2016;84:29‐40. ">Yousuf 2016</a>), brain haemorrhage (<a href="./references#CD008409-bbs2-0030" title="HsiehJT , LeiB , ShengH , VenkatramanT , LascolaCD , WarnerDS . Sex‐specific effects of progesterone on early outcome of intracerebral hemorrhage. Neuroendocrinology2016;103:518‐30. ">Hsieh 2016</a>), and neurodegenerative diseases (<a href="./references#CD008409-bbs2-0020" title="DeNicolaAF , Gonzalez DeniselleMC , GarayL , MeyerM , Gargiulo‐MonachelliG , GuennounR . Progesterone protective effects in neurodegeneration and neuroinflammation. Journal of Neuroendocrinology2013;25:1095‐103. ">De 2013</a>). </p> </section> <section id="CD008409-sec-0019"> <h3 class="title" id="CD008409-sec-0019">How the intervention might work</h3> <p>A great number of preclinical studies have reported a therapeutic effect of progesterone in the central nervous system. Progesterone is thought to decrease brain oedema and help to maintain the integrity of the blood‐brain barrier (<a href="./references#CD008409-bbs2-0027" title="HeL , ZhangX , WeiX , LiY . Progesterone attenuates aquaporin‐4 expression in an astrocyte model of ischemia/reperfusion. Neurochemical Research2014;39:2251‐61. ">He 2014</a>; <a href="./references#CD008409-bbs2-0044" title="SoltaniZ , KhaksariM , ShahrokhiN , MohammadiG , MofidB , VaziriA . Effect of estrogen and/or progesterone administration on traumatic brain injury‐caused brain edema: the changes of aquaporin‐4 and interleukin‐6. Journal of Physiology and Biochemistry2016;72:33‐44. ">Soltani 2016</a>; <a href="./references#CD008409-bbs2-0049" title="WangX , ZhangJ , YangY , DongW , WangF , WangL . Progesterone attenuates cerebral edema in neonatal rats with hypoxic‐ischemic brain damage by inhibiting the expression of matrix metalloproteinase‐9 and aquaporin‐4. Experimental and Therapeutic Medicine2013;6:263‐7. ">Wang 2013</a>), prevent apoptosis and necrosis (<a href="./references#CD008409-bbs2-0032" title="LiX , ZhangJ , ZhuX , WangP , WangX , LiD . Progesterone reduces inflammation and apoptosis in neonatal rats with hypoxic ischemic brain damage through the PI3K/Akt pathway. International Journal of Clinical and Experimental Medicine2015;8:8197‐203. ">Li 2015</a>; <a href="./references#CD008409-bbs2-0051" title="YousufS , AtifF , SayeedI , WangJ , SteinDG . Neuroprotection by progesterone after transient cerebral ischemia in stroke‐prone spontaneously hypertensive rats. Hormones and Behavior2016;84:29‐40. ">Yousuf 2016</a>), reduce excitotoxicity by lessening the effect of neuroinflammation, reduce oxidative stress and alter glutamate receptor activity (<a href="./references#CD008409-bbs2-0029" title="HongY , WangX , SunS , XueG , LiJ , HouY . Progesterone exerts neuroprotective effects against Aβ‐induced neuroinflammation by attenuating ER stress in astrocytes. International Immunopharmacology2016;33:83‐9. ">Hong 2016</a>; <a href="./references#CD008409-bbs2-0033" title="LuomaJI , KelleyBG , MermelsteinPG . Progesterone inhibition of voltage‐gated calcium channels is a potential neuroprotective mechanism against excitotoxicity. Steroids2011;76:845‐55. ">Luoma 2011</a>; <a href="./references#CD008409-bbs2-0050" title="WebsterKM , WrightDK , SunM , SempleBD , OzturkE , SteinDG . Progesterone treatment reduces neuroinflammation, oxidative stress and brain damage and improves long‐term outcomes in a rat model of repeated mild traumatic brain injury. Journal of Neuroinflammation2015;12:238. ">Webster 2015</a>), and improve motor, sensory and cognitive recovery (<a href="./references#CD008409-bbs2-0022" title="GeddesRI , PetersonBL , SteinDG , SayeedI . Progesterone treatment shows benefit in female rats in a pediatric model of controlled cortical impact injury. PLOS One2016;11:e0146419. ">Geddes 2016</a>; <a href="./references#CD008409-bbs2-0045" title="SteinDG . Progesterone exerts neuroprotective effects after brain injury. Brain Research Reviews2008;57(2):386‐97. ">Stein 2008</a>; <a href="./references#CD008409-bbs2-0048" title="WaliB , SayeedI , GuthrieDB , NatchusMG , TuranN , LiottaDC . Evaluating the neurotherapeutic potential of a water‐soluble progesterone analog after traumatic brain injury in rats. Neuropharmacology2016;109:148‐58. ">Wali 2016</a>). However, so far, none of these encouraging preclinical results have led to evidence of any considerable improvement in clinical outcomes. </p> </section> <section id="CD008409-sec-0020"> <h3 class="title" id="CD008409-sec-0020">Why it is important to do this review</h3> <p>The limited evidence from the last version of our review published in 2012 revealed that progesterone might improve the neurologic outcome of acute TBI patients (<a href="./references#CD008409-bbs2-0053" title="MaJ , HuangS , QinS , YouC . Progesterone for acute traumatic brain injury. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD008409.pub3] ">Ma 2012</a>). However, the previous systematic review has become outdated as the results of two recent phase III randomised controlled trials (RCTs) have now been published (<a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>; <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>). An updated review was needed to provide a comprehensive assessment of the best available evidence of the safety and efficacy of progesterone treatment for acute TBI. </p> <p>This updated systematic review of RCTs aims to quantify the evidence for the effects of progesterone administration on people with TBI. Because of the high incidence of TBI and its excessive cost each year, even a modest reduction in the risk of unfavourable outcomes could have major public health significance. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008409-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008409-sec-0021"></div> <p>To assess the effects of progesterone on neurologic outcome, mortality and disability in patients with acute TBI. To assess the safety of progesterone in patients with acute TBI. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008409-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008409-sec-0022"></div> <section id="CD008409-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008409-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included published randomised controlled trials (RCTs) of progesterone versus no progesterone (or placebo) for the treatment of acute TBI. In an attempt to improve the quality of our updated systematic review, we excluded non‐registered studies for which the study report was published after 2010 (<a href="./references#CD008409-bbs2-0041" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning health care is not fit for purpose and must change. BMJ2015;350:h2463. ">Roberts 2015</a>). </p> </section> <section id="CD008409-sec-0025"> <h4 class="title">Types of participants</h4> <p>People, of any age, with clinically diagnosed with acute TBI secondary to head injury. All severities of head injury were included. </p> </section> <section id="CD008409-sec-0026"> <h4 class="title">Types of interventions</h4> <p>Progesterone versus no progesterone or placebo, administered in any dose, by any route, for any duration and started within 24 hours of the head injury. </p> <p>We only considered natural progesterone as the intervention. Synthetic progestin has different effects to natural progesterone in postinjury treatment. Consequently, we did not include the following compounds as interventions: medroxyprogesterone, megestrol acetate, chlormadinone, hydroxyprogesterone, norethindrone, norgestrel nor norethynodrel (<a href="./references#CD008409-bbs2-0045" title="SteinDG . Progesterone exerts neuroprotective effects after brain injury. Brain Research Reviews2008;57(2):386‐97. ">Stein 2008</a>). </p> </section> <section id="CD008409-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD008409-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008409-list-0001"> <li> <p>Mortality at end of scheduled follow‐up</p> </li> <li> <p>Disability at end of scheduled follow‐up: assessed via the Glasgow Outcome Scale (GOS) and any other validated measures of neurological functioning and disability </p> </li> <li> <p>Intracranial pressure within the treatment period</p> </li> </ul> </p> </section> <section id="CD008409-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008409-list-0002"> <li> <p>Blood pressure</p> </li> <li> <p>Body temperature</p> </li> <li> <p>Complications and adverse events, including liver function abnormality, episodes of venous or arterial thromboembolism, allergic reactions, phlebitis </p> </li> </ul> </p> <p>To determine the optimal information size we assumed a 20% control event rate (mortality) and a 25% relative risk reduction with 90% power and a 0.05 significance level. Our calculations indicated that the optimal information size needed to reliably detect a plausible treatment effect in mortality is 1212 patients in each group. For the disability outcome (GOS 1 to 3), we assumed a 50% control event and a 25% relative risk reduction with 90% power and a 0.05 significance level. The optimal information size needed to reliably detect a plausible treatment effect in disability is 329 patients in each group. </p> </section> </section> </section> <section id="CD008409-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>The searches were not restricted by date, language or publication status.</p> <section id="CD008409-sec-0031"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Injuries Group's Information Specialist updated searches of the following electronic databases and trials registries (2012 to date): </p> <p> <ul id="CD008409-list-0003"> <li> <p>Cochrane Injuries Group's Specialised Register (30 September 2016);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; Issue 9, 2016, via Cochrane Register of Studies (CRSO)); </p> </li> <li> <p>MEDLINE (Ovid) (1950 to 30 September 2016);</p> </li> <li> <p>Embase (Ovid) (1980 to 30 September 2016);</p> </li> <li> <p>Web of Science Core Collection: Conference Proceedings Citation Index‐Science (CPCI‐S; 1990 to 30 September 2016); </p> </li> <li> <p>Clinicaltrials.gov (30 September 2016);</p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (30 September 2016). </p> </li> </ul> </p> <p>The full search strategies are presented in (<a href="./appendices#CD008409-sec-0090">Appendix 1</a>). </p> <p>Strategies for earlier searches (conducted in August 2012) are presented in (<a href="./appendices#CD008409-sec-0091">Appendix 2</a>). </p> </section> </section> <section id="CD008409-sec-0032"> <h3 class="title" id="CD008409-sec-0032">Data collection and analysis</h3> <section id="CD008409-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JM and YZ) independently screened the titles and abstracts of all citations found through the searches and decided whether or not the articles were potentially eligible for inclusion in the review. We obtained the full texts of all potentially relevant articles and the two review authors (JM and YZ) independently assessed whether each met the predefined inclusion criteria. We excluded any studies that did not fulfil the inclusion criteria, and the reasons for exclusion are noted in the '<a href="./references#CD008409-sec-0103" title="">Characteristics of excluded studies</a>' table. We resolved any disagreement by discussion or arbitration with SH. We examined all duplicate study reports to verify that they presented unique sets of data. </p> </section> <section id="CD008409-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JM and YZ) independently extracted data from the included studies on sequence generation, allocation concealment, loss to follow‐up, blinding of outcome assessment, types of participants, types of interventions, types of outcomes, methods of analysis (intention‐to‐treat (ITT) analysis or per protocol analysis, or both), comparability of groups at baseline, statistical methods used and source of study funding. Where necessary, we requested unpublished information from the study authors. We extracted data to allow an ITT method. For studies with a `modified ITT' method, if we had considered the reasons for exclusion of participants to be inappropriate and the data were available to the review author, we would have conducted analyses that include participants who were excluded by the study authors. We compared the data extracted by each author and resolved any disagreement by discussion or arbitration with SH. Data extracted are noted in the '<a href="./references#CD008409-sec-0102" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD008409-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JM and YZ) assessed RCTs using the 'Risk of bias' assessment tool in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008409-bbs2-0028" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Each review author independently evaluated risk of bias through assessing: sequence generation, allocation concealment, blinding (assessments were made for each main outcome or class of outcomes), incomplete outcome data (assessments were made for each main outcome or class of outcomes), selective outcome reporting and other sources of bias. We resolved any disagreement through discussion or arbitration from SH. We came to a judgement relating to the risk of bias for each domain and we also categorised the overall risk of bias of individual studiesas being at: low, high or unclear risk of bias as follows (<a href="./references#CD008409-bbs2-0028" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>): </p> <p> <ul id="CD008409-list-0004"> <li> <p>low risk of bias (i.e. plausible bias unlikely to alter the results seriously) if all domains were at low risk of bias; · </p> </li> <li> <p>unclear risk of bias (i.e. plausible bias that raises some doubt about the results) if one or more domains had an unclear risk of bias; </p> </li> <li> <p>high risk of bias (i.e. plausible bias that seriously weakens confidence in the results) if one or more domains were at high risk of bias. </p> </li> </ul> </p> </section> <section id="CD008409-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the risk ratio (RR) and 95% confidence interval (CI) for mortality. We split GOS data into favourable (moderate disability, good recovery; GOS scores 4 and 5) and unfavourable outcomes (death, vegetative state, severe disability; GOS scores 1 to 3). We would have split other validated functional outcome data into favourable (modified Rankin Scale score&lt;3, Barthel Index&gt;60, etc) and unfavourable outcomes (modified Rankin Scale score graded 3 to 6 and Barthel Index 0 to 60,etc).These were also calculated by RR and 95% CI. For continuous outcomes such as intracranial pressure, body temperature, and blood pressure, we would have used arithmetic means and standard deviations for each group. </p> </section> <section id="CD008409-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to obtain missing information. When the missing data were unavailable, we included data on only those particpants whose results were known to generate the outcome and considered the potential impact of the missing data during the interpretation of the results. </p> </section> <section id="CD008409-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity between comparable trials by examining the participants, interventions and outcomes of the trials. In addition, we used visual inspections of graphs to assess heterogeneity. Statistical heterogeneity was examined with the I² statistic and Chi² test. Substantial heterogeneity was considered to exist when I² exceeded 60% and the Chi² test P value was less than 0.1. </p> </section> <section id="CD008409-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting bias by funnel plots and linear regression tests, however, there were too few included studies to enable meaningful analysis. We will assess reporting biases in future updates if there are 10 or more studies included in the meta‐analysis. </p> </section> <section id="CD008409-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We calculated the RRs and 95% CIs via a fixed‐effect model and conducted a meta‐analysis for dichotomous outcomes, if we judged that the included trials were clinically and statistically homogeneous. We employed the random‐effects model to pool studies when statistical heterogeneity occurred. For continuous data, we would have calculated mean differences (MD) or standardised mean differences (SMD) with 95% CI. We assessed possible sources of heterogeneity by subgroup and sensitivity analyses. We used <a href="./references#CD008409-bbs2-0040" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> software, version 5.3 for all analyses. </p> </section> <section id="CD008409-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following subgroup analysis by severity of brain injury:</p> <p>severe TBI subgroup (Glasgow Coma Scale (GCS) ≤ 8) and moderate TBI subgroup (GCS 9 to 12). </p> </section> <section id="CD008409-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses to assess the robustness of the results, by excluding studies with an unclear or high risk of bias for allocation concealment. </p> <section id="CD008409-sec-0043"> <h5 class="title">Summarising findings and assessing the quality of the evidence</h5> <p>We developed a 'Summary of findings' table to present the results of this review. We included all outcomes: mortality, disability, intracranial pressure; blood pressure, body temperature, and complications and adverse events. </p> <p>Where possible, we assessed the quality of the evidence for our effect estimates using the GRADE methods to account for the overall risk of bias of the included studies, inconsistency of the results, indirectness of the evidence, precision of the estimates and the risk of publication bias (<a href="./references#CD008409-bbs2-0025" title="GRADE working group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐7. ">GRADE 2004</a>). This was done independently and in duplicate by JM and YZ. We rated the quality of the evidence as high, moderate, low or very low. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008409-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008409-sec-0044"></div> <section id="CD008409-sec-0045"> <h3 class="title">Description of studies</h3> <p>We identified five completed studies that satisfied the inclusion criteria using the process described in <a href="#CD008409-fig-0001">Figure 1</a> (<a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>; <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>; <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>; <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>; <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>). All trials eligible for inclusion compared progesterone therapy with a control group. There were also three ongoing trials (<a href="./references#CD008409-bbs2-0014" title="KhaksariM . Effect of female sex hormones on traumatic brain injury [Evaluation of the efficacy and probable mechanism of estrogen and progesteron on the complications of moderate and severe diffuse traumatic brain injury in patients admitted in Kerman Shahid Bahonar Hospital: a clinical trial]. www.irct.ir/searchresult.php?id=17356&amp;number=1 2014 (accessed 30 September 2016). ">IRCT2014042017356N1</a>; <a href="./references#CD008409-bbs2-0012" title="SinhaS . A clinical trial of progesterone with or without hypothermia in patients with severe head injury [A randomized placebo controlled trial (factorial design) of progesterone with or without hypothermia in subjects with acute severe traumatic brain injury]. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1048 2011 (accessed 30 September 2016). ">CTRI/2009/091/000893</a>, <a href="./references#CD008409-bbs2-0013" title="SinhaS . A clinical trial to Investigate the efficacy of progesterone in patients with severe traumatic brain injury [A randomized, placebo‐controlled study to investigate the efficacy of progesterone in patients with severe traumatic brain injury]. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3871 2013 (accessed 30 September 2016). ">CTRI/2013/02/003396</a>), which are detailed in <a href="./references#CD008409-sec-0104" title="">Characteristics of ongoing studies</a>. </p> <div class="figure" id="CD008409-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008409-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD008409-sec-0046"> <h4 class="title">Included studies</h4> <p>Full descriptions of all the included studies can be found in the <a href="./references#CD008409-sec-0102" title="">Characteristics of included studies</a>. </p> <p>The five included studies had a total of 2392 participants; 1195 in <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>;100 in <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>; 882 in <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>; 56 in <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>; and 159 in <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>. </p> <p><a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>: was a Mmulticenter phase III RCT that randomly assigned participants. Patients, (16 to 70 years of age, with severe TBI (GCS ≤ 8 and at least one reactive pupil)) were randomly assigned to receive progesterone or placebo. The modified ITT population excluded 16 participants (6 participants in the progesterone group and 10 in the placebo group) because they did not receive any study drug. Drug infusion (progesterone andor placebo) was started intravenously within 8eight hours afterof injury with a loading dose of 0.71 mg/kg/hour for one hour, followed by 0.50 mg/kg/hour for 119 hours. </p> <p><a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> was a phase II RCT that recuited adults with acute severe TBI and a GCS score of 4 to 12 after resuscitation, and stabilisation within 11 hours of injury. Participants were assigned to eight clinical subgroups, then permuted block randomisation assigned four of every five consecutive patients to progesterone and the other to placebo. A 4:1 randomisation scheme was used to increase the number of patients receiving progesterone while maintaining blinding. The progesterone group received an infusion of 0.71 mg/kg of progesterone at 14 mL/h for the first hour and then an infusion of 0.5 mg/kg progesterone in 10 mL/h for the next 11 hours. Five additional 12‐hour maintenance infusions were delivered at the standard rate of 10 mL/hour, for a total of three days of treatment; the control group received placebo. </p> <p><a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>: was a Mmulticenter phase III RCT that recruited a. Adults patients with brain injury (GCS score of 4 to 12) were enrolled if the study treatment could be initiated within 4four hours afterof the injury. The study drug (progesterone or placebo) was infused continuously through a dedicated intravenous catheter at a dose of 14.3 mlL/h per hour for 1one hour and then at 10 mL/l per hour for 71 hours; the dose was then tapered by 2.5 mlL/ per hour every 8eight hours, for a total treatment duration of 96 hours. </p> <p><a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> recruited patients aged 15 to 65 years with severe TBI (GCS 5 to 8) after the time of injury, and randomised them according to a random number table. The progesterone group received 80 mg progesterone via intramuscular injection once every 12 hours for five consecutive days. </p> <p><a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> recruited adults with acute severe TBI and a GCS score ≤ 8 after resuscitation, and stabilisation within eight hours of injury. Participants were randomised according to a random number table. The progesterone group received a dose of progesterone of 1.0 mg/kg via intramuscular injection within eight hours of the time of injury, and then every 12 hours for five consecutive days. The control group received placebo. </p> </section> <section id="CD008409-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of six studies (<a href="./references#CD008409-bbs2-0006" title="AbokhabarH , AbouelelaA , MousaS . Impact of progesterone administration on outcome of patients with severe traumatic brain injury. Intensive Care Medicine. 2012. ">Abokhabar 2012</a>; <a href="./references#CD008409-bbs2-0007" title="AminmansourB , NikbakhtH , GhorbaniA , RezvaniM , RahmaniP , TorkashvandM . Comparison of the administration of progesterone versus progesterone and vitamin D in improvement of outcomes in patients with traumatic brain injury: a randomized clinical trial with placebo group. Advanced Biomedical Research2012;1:58. ">Aminmansour 2012</a>; <a href="./references#CD008409-bbs2-0008" title="MofidB , SoltaniZ , KhaksariM , ShahrokhiN , NakhaeeN , KaramouzianS . What are the progesterone‐induced changes of the outcome and the serum markers of injury, oxidant activity and inflammation in diffuse axonal injury patients?. International Immunopharmacology2016;32:103‐10. ">Mofid 2016</a>; <a href="./references#CD008409-bbs2-0009" title="RahejaA , SinhaS , SamsonN , BhoiS , SubramanianA , SharmaP . Serum biomarkers as predictors of long‐term outcome in severe traumatic brain injury: analysis from a randomized placebo‐controlled Phase II clinical trial. Journal of Neurosurgery2016;125:631‐41. ">Raheja 2016</a>; <a href="./references#CD008409-bbs2-0010" title="ShakeriM , BoustaniMR , PakN , PanahiF , SalehpourF , LotfiniaI . Effect of progesterone administration on prognosis of patients with diffuse axonal injury due to severe head trauma. Clinical Neurology and Neurosurgery2013;115:2019‐22. ">Shakeri 2013</a>; <a href="./references#CD008409-bbs2-0011" title="WrightDW , RitchieJC , MullinsRE , KellermannAL , DensonDD . Steady‐state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. Journal of Clinical Pharmacology2005;45:640‐8. ">Wright 2005</a>). </p> <p>We excluded three studies because they were not prospectively registered and their reports were published after 2010. These included <a href="./references#CD008409-bbs2-0007" title="AminmansourB , NikbakhtH , GhorbaniA , RezvaniM , RahmaniP , TorkashvandM . Comparison of the administration of progesterone versus progesterone and vitamin D in improvement of outcomes in patients with traumatic brain injury: a randomized clinical trial with placebo group. Advanced Biomedical Research2012;1:58. ">Aminmansour 2012</a> and <a href="./references#CD008409-bbs2-0006" title="AbokhabarH , AbouelelaA , MousaS . Impact of progesterone administration on outcome of patients with severe traumatic brain injury. Intensive Care Medicine. 2012. ">Abokhabar 2012</a> for which we were unable to locate registration or protocols. <a href="./references#CD008409-bbs2-0008" title="MofidB , SoltaniZ , KhaksariM , ShahrokhiN , NakhaeeN , KaramouzianS . What are the progesterone‐induced changes of the outcome and the serum markers of injury, oxidant activity and inflammation in diffuse axonal injury patients?. International Immunopharmacology2016;32:103‐10. ">Mofid 2016</a> claimed it was a prospective, single‐blind RCT performed from May 2013 to July 2015. However, we found the study protocol was approved by ethics committee of Kerman University of Medical Sciences in April 2014 and registered in the Iranian Registry of Clinical Trials in August 2014 (<a href="http://www.irct.ir, CT2014042017356N1" target="_blank">www.irct.ir, CT2014042017356N1</a>). Because of this delay in trial registration, we judged that the study had not been prospectively registered. </p> <p>We excluded two studies because they used biochemical outcome measures and did not address clinical outcomes. <a href="./references#CD008409-bbs2-0011" title="WrightDW , RitchieJC , MullinsRE , KellermannAL , DensonDD . Steady‐state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. Journal of Clinical Pharmacology2005;45:640‐8. ">Wright 2005</a> evaluated the pharmacokinetics of progesterone given by intravenous infusion to people with TBI, while <a href="./references#CD008409-bbs2-0009" title="RahejaA , SinhaS , SamsonN , BhoiS , SubramanianA , SharmaP . Serum biomarkers as predictors of long‐term outcome in severe traumatic brain injury: analysis from a randomized placebo‐controlled Phase II clinical trial. Journal of Neurosurgery2016;125:631‐41. ">Raheja 2016</a> was part of a prospective blinded, randomized, placebo‐controlled phase II trial of progesterone with or without hypothermia (<a href="./references#CD008409-bbs2-0012" title="SinhaS . A clinical trial of progesterone with or without hypothermia in patients with severe head injury [A randomized placebo controlled trial (factorial design) of progesterone with or without hypothermia in subjects with acute severe traumatic brain injury]. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1048 2011 (accessed 30 September 2016). ">CTRI/2009/091/000893</a>), which focused on the relationship between serum biomarkers and outcomes after TBI; the study report did not include the effect of progesterone on TBI. </p> <p>We excluded <a href="./references#CD008409-bbs2-0010" title="ShakeriM , BoustaniMR , PakN , PanahiF , SalehpourF , LotfiniaI . Effect of progesterone administration on prognosis of patients with diffuse axonal injury due to severe head trauma. Clinical Neurology and Neurosurgery2013;115:2019‐22. ">Shakeri 2013</a> because medroxyprogesterone was used as the intervention rather than progesterone. </p> </section> </section> <section id="CD008409-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>Our assessments of the risk of bias in the included studies are recorded in the 'Risk of bias' tables, and are displayed in <a href="#CD008409-fig-0002">Figure 2</a> and <a href="#CD008409-fig-0003">Figure 3</a>. The overall risk of bias of individual studies was judged as high for <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> and <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, unclear for <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>, and low for <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>. </p> <div class="figure" id="CD008409-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Five studies are included in this review." data-id="CD008409-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Five studies are included in this review. </p> </div> </div> </div> <div class="figure" id="CD008409-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008409-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008409-sec-0049"> <h4 class="title">Allocation</h4> <section id="CD008409-sec-0050"> <h5 class="title">Sequence generation</h5> <p><a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> assigned four of every five consecutive participants to progesterone and the fifth to placebo via permuted block randomisation. </p> <p>In <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> and <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, participants were allocated according to a random number table. </p> <p>In <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>, randomisation was performed with the use of a combination of minimisation and biased‐coin algorithms. </p> <p>In <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>, randomisation was implemented with the use of an interactive web‐based response system. </p> <p>The risk of bias for this domain was judged to be low for all five studies.</p> </section> <section id="CD008409-sec-0051"> <h5 class="title">Allocation concealment</h5> <p>In <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>, the appearance, packaging and administration of placebo and progesterone injections were the same for the two groups. <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> did not describe the methods used for allocation concealment sufficiently for us to determine the risk of bias for this domain. We therefore assessed this study as being at unclear risk of bias. </p> <p>The risk of bias for this domain was judged as low for <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>, and unclear for <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>. </p> </section> </section> <section id="CD008409-sec-0052"> <h4 class="title">Blinding</h4> <section id="CD008409-sec-0053"> <h5 class="title">Blinding (GOS and other objective outcomes)</h5> <p><a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> and <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> mentioned `double blinding', and achieved blinding by use of indistinguishable drug kits. We judged the risk of bias for this domain as low for these trials. </p> <p>In the trial by <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>, there was no blinding and the outcome measurement was likely to be influenced by lack of blinding. We judged the risk of bias for this domain as high. </p> </section> <section id="CD008409-sec-0054"> <h5 class="title">Blinding (mortality)</h5> <p>We decided that for the outcome of mortality, the outcome and its measurement were not likely to have been influenced by blinding. So we judged the risk of bias for this domain to be low for all included studies. </p> </section> </section> <section id="CD008409-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, with the exception of three people who discontinued treatment (two died during infusion, one was taken into police custody), there were no withdrawals, dropouts, or losses to follow‐up by the end of the follow‐up period. In <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, there were two withdrawals, three dropouts and 19 losses to follow‐up at the end of the follow‐up period. In <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>, a total of 31 participants (17 in the progesterone group and 14 in the placebo group) were lost to follow‐up. <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> used a modified ITT population and excluded 16 participants (six in the progesterone group and 10 in the placebo group) because they did not receive any study drug. This method was described previously in its protocol, so we did not consider these exclusions were associated with industry funding or authors' conflicts of interest. In <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>, 28 participants (6.3%) in progesterone group and 24 (5.5%) in placebo group were missing. Missing outcome data was balanced in numbers between progesterone group and placebo group in all of the above four studies. Attrition or exclusion of participants was not reported in <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>. </p> <p>We judged the risk of bias for this domain as low for <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> and <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>, and as unclear for <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>. </p> </section> <section id="CD008409-sec-0056"> <h4 class="title">Selective reporting</h4> <p>The protocols for <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> were presented in Clinicaltrials.gov. It was clear that these published reports included all expected outcomes, so we judged the risk of bias for this domain as low for <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>. </p> <p><a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> and <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> were registered in the Australian New Zealand Clinical Trials Registry (ACTRN12607000545460) and the Chinese Clinical Trial Register (ChiCTR‐TRC‐08000174), but this was done retrospectively. The dates of registration postdated the ends of the trials. We did not exclude these two trials because they were published before 2010 (<a href="./references#CD008409-bbs2-0041" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning health care is not fit for purpose and must change. BMJ2015;350:h2463. ">Roberts 2015</a>). We judged the risk of bias for selective reporting as high for these two trials. </p> </section> <section id="CD008409-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <section id="CD008409-sec-0058"> <h5 class="title">Source of funding</h5> <p><a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> and <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> were supported by a grant from the National Institute for Neurological Disorders and Stroke, National Institutes of Health, USA. </p> <p><a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> and <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> were supported by the Scientific Research Fund of Zhejiang Provincial Education Department, China. </p> <p><a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> was funded by BHR Pharma, UK. </p> </section> <section id="CD008409-sec-0059"> <h5 class="title">Stopping a trial early</h5> <p>The <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> trial intended to enrol 1140 participants, but the trial was abandoned after 882 people had been assessed. We did not consider reporting bias, because there was no selective revealing or suppression of the study information. After the second interim analysis, the trial was stopped because of futility (favourable outcomes were observed in 51% of participants who received progesterone after TBI, compared with 55.5% of controls. Stratification of the participants on the basis of injury severity did not reveal any effect of progesterone on recovery). We therefore assessed the risk of other bias for <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> as unclear. </p> </section> <section id="CD008409-sec-0060"> <h5 class="title">Centre effects in multicenter RCTs</h5> <p><a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> was conducted in approximately 100 centres in 21 countries. The number of mortality or functional outcome events in each centre was quite low. We assessed potential bias from variation between‐centres as unclear because of factors such as different levels of expertise in treating TBI and outcome assessment. </p> <p><a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> was conducted in 22 academic medical centres through the National Institute of Neurological Disorders and Stroke‐funded Neurological Emergencies Treatment Trials network in the USA. We considered the potential bias from centre effects in this trial to be low. </p> </section> </section> </section> <section id="CD008409-sec-0061"> <h3 class="title" id="CD008409-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD008409-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD008409-sec-0062"> <h4 class="title">Mortality</h4> <p>Overall mortality was evaluated in all five trials at the end of follow‐up (i.e. 30 days postinjury in <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, three months postinjury in <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>, and six months postinjury in <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>).There was no evidence of a difference in mortality between the treatment and placebo groups. We assessed the quality of this evidence to be low (see <a href="./full#CD008409-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>The ITT analysis included 2376 participants pooled for meta‐analysis. The pooled RR of death at the end of follow‐up was 0.91 (95% CI 0.65 to 1.28, P value 0.60). We used a random‐effects model as there was substantial heterogeneity (Tau² = 0.08; Chi² = 10.40, df = 4 (P = 0.03); I² = 62%; <a href="./references#CD008409-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD008409-sec-0063"> <h4 class="title">Disablity</h4> <p>All the included studies reported disability data assessed by GOS score. GOS data in <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> , <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> were sufficient to be dichotomised into favourable outcomes (moderate disability, good recovery; GOS 4 and 5) and unfavourable outcomes (sometimes referred to as unfavourable functional recovery: i.e. death, vegetative state, severe disability; GOS 1 to 3). Only <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> reported the mean GOS at three months postinjury, and these data were insufficient to dichotomise into favourable and unfavourable outcomes. </p> <p>We pooled unfavourable outcomes (death, vegetative state, severe disability; GOS 1 to 3) for four trials at the end of follow‐up (i.e. 30 days postinjury in <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, six months postinjury in <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> and <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>). There was no evidence of a difference between the treatment and placebo groups and no substantial heterogeneity (RR = 0.98, 95% CI 0.89 to 1.06, P value 0.58; Chi² = 4.77, df = 3 (P = 0.19); I² = 37%; <a href="./references#CD008409-fig-0005" title="">Analysis 1.2</a>). We assessed the quality of this evidence to be moderate (see <a href="./full#CD008409-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, disability in survivors was also assessed by the Disability Rating Score (DRS) at 30 days postinjury. Survivors with severe TBI in the placebo group were slightly less likely to be disabled than those in the progesterone group (DRS = 10.7, 95% CI 8.3 to ‐13.1 for progesterone‐treated participants versus DRS = 4.4, 95% CI 0.0 to 9.8 for placebo‐treated participants). The authors explained that a higher proportion of severely injured participants treated with progesterone survived, so survivors in the progesterone group may have been slightly more disabled. In the moderate TBI stratum, participants treated with progesterone were significantly less disabled than those who received placebo (DRS = 5.0, 95% CI 1.8 to 6.2 for progesterone‐treated participants versus DRS = 12.7, 95% CI 7.6 to 17.78 for placebo‐treated participants). The authors did not report a test for interaction between the high and moderate brain injury strata. </p> <p><a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> and <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> presented data showing reduced disability in the progesterone therapy group relative to the control. However, these were the small studies and assessed to be at high overall risk of bias. We do not consider these data to outweigh the evidence from the much larger meta‐analysis. In <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>, disability data were assessed using GOS score, Karnofsky Performance Scale (KPS), verbal and motor function at three months postinjury. For GOS, a higher score equates to less disability, whilst for KPS, verbal and motor function scores, a lower score equates to lower disability. All of these data were presented as means and standard deviations in a table as follows: </p> <p> <ul id="CD008409-list-0005"> <li> <p>the GOS score in the progesterone group was 5.0 ± 1.7 and in the control group was 4.0 ± 1.9, P &lt; 0.05 </p> </li> <li> <p>the KPS score in the progesterone group was 4.9 ± 1.2 and in the control group was 4.0 ± 1.1, P &lt; 0.05; </p> </li> <li> <p>verbal function in the progesterone group was 3.1 ± 0.4 and in the control group was 2.3 ± 0.7, P &lt; 0.05; </p> </li> <li> <p>motor function in the progesterone group was 2.4 ± 0.7 and in the control group was 2.4 ± 0.4, P &gt; 0.05. </p> </li> </ul> </p> <p>No other details about these data were reported.</p> <p>In <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, disability was also assessed by Modified Functional Independence Measure (FIM) scores, where a higher score equates to less disability. At the three‐month follow‐up, the scores were 7.35 ± 1.89 for the placebo group and 8.02 ± 1.73 for the progesterone group (P &lt; 0.05). At six months after injury, the scores were 8.95 ± 1.05 for the placebo group and 9.87 ± 1.17 (P &lt; 0.01) for the progesterone group. </p> </section> <section id="CD008409-sec-0064"> <h4 class="title">Intracranial pressure (ICP)</h4> <p><a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> reported intracranial pressure (ICP) data, but we were not able to perform meta‐analysis due to variations in the way the data were presented. <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> presented ICP data as mean values, while <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> presented them as the mean frequency of pressures exceeding threshold values, and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> presented them as the proportion with increased ICP. </p> <p>In <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, the mean ICP level of the progesterone group remained stable, whereas that of the control group tended to increase during the first three days of treatment and for one day after treatment However, this trend was not significant. The mean ICP‐therapeutic intensity level scores presented did not differ between groups. </p> <p>In <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, there was no evidence of a difference between the two groups for mean ICP at 24 hours after trauma (progesterone group, 22.1 ± 4.3 mmHg versus placebo group, 23.2 ± 4.6 mmHg; P value 0.121). At 72 hours and at seven days after injury, there was still no evidence of a difference in the mean ICP of participants who were given progesterone and participants who received placebo (16.9 ± 3.8 mmHg and 14.8 ± 3.8 mmHg for progesterone treated participants versus 18.2 ± 5.1 mmHg and 15.9 ± 4.1 mmHg for placebo‐treated participants, respectively; P &gt; 0.05). </p> <p>In <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>, the ICP of 130 participants in the progesterone group increased, as did the ICP of 137 participants in the placebo group. There was no evidence of a difference between the two groups. </p> </section> <section id="CD008409-sec-0065"> <h4 class="title">Body temperature</h4> <p>No data for body temperature were available for meta‐analysis.</p> <p><a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> collected detailed data on body temperature. Throughout the three‐day infusion period, the progesterone group experienced a lower increase in mean temperature than the control group; this was determined through analysis of a treatment‐by‐time interaction term for progesterone versus control participants, with had a slope of 0.0055 (95% CI ‐0.010 to ‐0.001). </p> </section> <section id="CD008409-sec-0066"> <h4 class="title">Blood pressure</h4> <p>No data for blood pressure were available for meta‐analysis.</p> <p><a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> collected detailed data on blood pressure. Throughout the three‐day infusion interval, there was no evidence of a difference between the progesterone and placebo groups. </p> </section> <section id="CD008409-sec-0067"> <h4 class="title">Adverse events</h4> <p>A pooled analysis was not appropriate for adverse event data, so we have presented the data narratively. </p> <p><a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> reported serious adverse events and adverse event rates for the progesterone‐treated group and the placebo‐treated group. There was no evidence of a difference in the rates of adverse and serious adverse events between groups. The only adverse event attributed to progesterone was a case of superficial phlebitis at the intravenous site. </p> <p><a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> did not report the specifics of any adverse events in either group, but did report that there were no additional adverse events after administration of progesterone and no further late toxicity up to six months. </p> <p><a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> reported the rates of all reported adverse events and serious adverse events. Only phlebitis or thrombophlebitis was reported to be significantly more frequent in the progesterone group than in the placebo group (882 cases, RR 3.03; 95% CI, 1.96 to 4.66). </p> <p><a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> recorded adverse events for the first 15 days, and serious adverse events were recorded throughout the duration of the study. There was no evidence of a difference in the rate of adverse events between the progesterone and placebo groups. </p> </section> <section id="CD008409-sec-0068"> <h4 class="title">Subgroup analysis (severity of TBI)</h4> <p>The <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> and <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> trials involved 281 participants with moderate TBI and 701 participants with severe TBI. The <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>, <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> studies enrolled a total of 1410 participants with severe TBI, but did not enrol people with moderate TBI. When we limited our analysis to the severe TBI subgroup or moderate TBI subgroup, there were minimal changes in the results. </p> <p>In the severe TBI subgroup (GCS ≤ 8), the pooled RR for mortality at the end of follow‐up was 0.87 (95% CI 0.60 to 1.27; P value 0.48; 2111 participants, 2090 pooled for meta‐analysis). We used a random‐effects model as there was substantial heterogeneity (Tau² = 0.10; Chi² = 11.60, df = 4 (P value 0.02); I² = 66%). In the moderate TBI subgroup (GCS = 9 to 12) the pooled RR for mortality at the end of follow‐up was 1.30 (95% CI 0.70 to 2.41; P value 0.40; 281 participants, 279 pooled for meta‐analysis).There was no substantial heterogeneity (Chi² = 0.01, df = 1 (P = 0.91); I² = 0%). The test for subgroup differences showed no evidence that progesterone therapy has a differential effect on these two subgroups (P value 0.28) (<a href="./references#CD008409-fig-0006" title="">Analysis 2.1</a>). </p> <p>The pooled RR in the severe TBI subgroup for death or severe disability (GOS 1 to 3) at the end of follow‐up was 0.99 (95% CI 0.87 to 1.11; P value 0.80; 2055 participants, 2002 pooled for meta‐analysis). There was no substantial heterogeneity (Chi² = 4.25, df = 3 (P value 0.24); I² = 29%). The pooled RR in the moderate group for death or severe disability (GOS 1 to 3) at the end of follow‐up was 0.68 (95% CI 0.34 to 1.37 ; P value 0.28; 281 participants, 258 pooled for meta‐analysis); we used a random‐effects model as there was substantial heterogeneity (Tau² = 0.20; Chi² = 4.41, df = 1 (P = 0.04); I² = 77%). The test for subgroup differences showed no evidence that progesterone therapy had a differential effect on these two subgroups (P value 0.31). (<a href="./references#CD008409-fig-0007" title="">Analysis 2.2</a>). </p> </section> <section id="CD008409-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>When we removed studies that did not report allocation concealment procedures from the analysis, there was still no evidence of a difference in mortality (RR 0.88, 95% CI 0.60 to 1.28) or disability (unfavourable outcomes: death, vegetative state, severe disability; GOS 1 to 3) (RR 0.98, 95% CI 0.89 to 1.06) between the progesterone and placebo groups (<a href="./references#CD008409-fig-0008" title="">Analysis 3.1</a>; <a href="./references#CD008409-fig-0009" title="">Analysis 3.2</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008409-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008409-sec-0070"></div> <section id="CD008409-sec-0071"> <h3 class="title" id="CD008409-sec-0071">Summary of main results</h3> <p>We included five completed studies with 2392 participants. The main results are presented in the 'Summary of findings' table (<a href="./full#CD008409-tbl-0001">summary of findings Table for the main comparison</a>). The results of the meta‐analyses did not find evidence that progesterone could improve overall mortality (RR 0.91, 95% CI 0.65 to 1.28; P = 0.60, I² = 62%; 2376 participants; low quality evidence) nor disability (unfavourable outcomes: death, vegetative state, severe disability; GOS 1 to 3) (RR 0.98, 95% CI 0.89 to 1.06; P = 0.58, I² = 37%; 2260 participants; moderate quality evidence) in participants with TBI. When we performed a subgroup analysis on participants with severe TBI versus moderate TBI, and tested for a difference between subgroups, there was no evidence of a difference between the two groups. When we performed sensitivity analysis and removed the study without adequate allocation concealment procedures from analysis, there were no significant changes to the results. </p> <p>Data were not available for meta‐analysis for the outcomes of mean intracranial pressure, blood pressure, body temperature and adverse events. However, data from three studies showed no evidence of a difference in mean intracranial pressure among participants in either group. Data from one study showed no evidence of a difference in blood pressure and body temperature between the progesterone and placebo groups. Intravenous progesterone infusion increased the frequency of phlebitis in one trial. There was no evidence of a difference in the rate of other adverse events between progesterone treatment and placebo in the other three studies that looked at adverse events. </p> </section> <section id="CD008409-sec-0072"> <h3 class="title" id="CD008409-sec-0072">Overall completeness and applicability of evidence</h3> <section id="CD008409-sec-0073"> <h4 class="title">Completeness</h4> <p>We were only able to perform meta‐analysis for two of our three primary outcomes (mortality and disability), as ICP was presented in three different formats in the three trials that looked at this outcome. For our secondary outcomes, blood pressure and body temperature were only recorded in one of our five included trials (<a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>), which limits the completeness of our results. </p> <p>We were unable to obtain some information regarding the trial described in <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>. We judged the allocation concealment as unclear due to a lack of information in the study report. In addition, in this trial the data for GOS score were presented by mean difference and 95% CI in a table. These data were insufficient to calculate the pooled RR for disability. We tried to contact the study authors of <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> to request details, but we did not receive a response. </p> </section> <section id="CD008409-sec-0074"> <h4 class="title">Applicability</h4> <p>In terms of the applicability of our results, TBI patients are highly diverse in terms of aetiology, pathology, function and outcome, which leads to concerns that progesterone may affect the recovery of different TBI patients differentially. This is supported by the fact that although we performed subgroup analysis according to GCS grade, there was still high heterogeneity within these subgroups. This means that the results of the meta‐analyses should be interpreted with caution. We discuss the issue of heterogeneity among TBI patients in more detail under '<a href="#CD008409-sec-0075">Quality of the evidence</a> ‐ Categorisation of TBI'. </p> </section> </section> <section id="CD008409-sec-0075"> <h3 class="title" id="CD008409-sec-0075">Quality of the evidence</h3> <p>According to the GRADE approach to assessing the quality of the evidence in the included studies (<a href="./full#CD008409-tbl-0001">summary of findings Table for the main comparison</a>), we classified the quality of the evidence as low for mortality, and moderate for disability (unfavourable outcomes: death, vegetative state, severe disability; GOS 1 to 3)). </p> <p>Although the overall risk of bias of two included studies was judged as high (<a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a>; <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>), and unclear for two studies (<a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>; <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>), most of the data were from studies that were judged to be at low risk of bias across most domains, with no domains at high risk of bias, so we did <i>not</i> downgrade for risk of bias. </p> <p>Although most of the trials included in this review were well conducted, several factors did influence our assessment of the quality of the overall body of evidence. Firstly, although subgroup analyses were performed according to the protocol, there was still substantial statistical heterogeneity. Secondly, there were three different time points involved in the analysis of mortality and two different time points involved in the analysis of unfavourable outcomes. Thirdly, the dosage, treatment routine and vehicles of progesterone varied across studies. Finally, we had concerns regarding the heterogeneity among TBI patients, and the fact that progesterone may affect TBI patients differentially. </p> <section id="CD008409-sec-0076"> <h4 class="title">Time at the end of follow‐up</h4> <p>For the mortality and disability outcome we pooled mortality and GOS scores at the end of the follow‐up in each trial; for <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a> this was 30 days postinjury, for <a href="./references#CD008409-bbs2-0004" title="XiaoGM , WeiJ , WuZH . Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi2007;45(2):106‐8. ">Xiao 2007</a> this was three months, and for <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>; <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a>; <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> this was six months. We should consider this as an inconsistency that has an impact on our confidence in our conclusions. </p> </section> <section id="CD008409-sec-0077"> <h4 class="title">Dosage, mode of delivery and schedule of progesterone therapy</h4> <p>The dosage used in <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, <a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> and <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a> was six times that used in <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a> (approximately 12 mg/kg/day versus 2 mg/kg/day). The schedule and mode of delivery also varied between trials. This may explain the existence of significant heterogeneity. Examination of the pharmacokinetics of progesterone intravenous infusion in demonstrated that stable progesterone concentrations can be achieved rapidly via progesterone infusion following TBI. Unfortunately, none of the studies used allometric scaling to determine the most effective dose for humans based on the preclinical animal research (<a href="./references#CD008409-bbs2-0021" title="Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Available from www.fda.gov. ">FDA 2005</a>; <a href="./references#CD008409-bbs2-0038" title="NairAB , JacobS . A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy2016;7:27‐31. ">Nair 2016</a>), and there was no attempt to optimise either dose or schedule as part of any included study. It is possible that none of the doses in the included RCTs was optimal for improving motor, sensory and memory function according to preclinical dose‐response studies (<a href="./references#CD008409-bbs2-0046" title="SteinDG . Embracing failure: what the Phase III progesterone studies can teach about TBI clinical trials. Brain Injury2015;29:1259‐72. ">Stein 2015</a>; <a href="./references#CD008409-bbs2-0047" title="WaliB , IshratT , WonS , SteinDG , SayeedI . Progesterone in experimental permanent stroke: a dose‐response and therapeutic time‐window study. Brain2014;137:486‐502. ">Wali 2014</a>). </p> </section> <section id="CD008409-sec-0078"> <h4 class="title">Categorisation of TBI</h4> <p>TBI is categorised according to GCS score on admission to hospital to estimate the severity of the underlying injury. As we know, TBI is regarded as a very heterogeneous and complex disease, with substantial heterogeneity in the aetiology, pathology, mechanisms, exposure time and outcome. There are obvious limitations to using the GCS for the classification of such a complicated disease (<a href="./references#CD008409-bbs2-0034" title="MaasAI , MenonDK , LingsmaHF , PinedaJA , SandelME , ManleyGT . Re‐orientation of clinical research in traumatic brain injury: report of an international workshop on comparative effectiveness research. Journal of Neurotrauma2012;29:32‐46. ">Maas 2012</a>). The diverse mechanisms of TBI, as well as differences in age and gender, also lead to different potential for functional recovery and response to progesterone. Use of a 'one size fits all' approach for these different types of TBI is not appropriate (<a href="./references#CD008409-bbs2-0037" title="MeyfroidtG , TacconeFS . Another failed attempt of neuroprotection: progesterone for moderate and severe traumatic brain injury. Minerva Anestesiologica2016;82:486‐91. ">Meyfroidt 2016</a>). Recently, an increasing number of articles suggest a more individualised classification and subgroup analysis of TBI based on biomarkers, age, gender, and clinical characteristics and imaging findings to identify the appropriate patients for progesterone therapy after acute TBI (<a href="./references#CD008409-bbs2-0036" title="MenonDK , MaasAI . Traumatic brain injury in 2014. Progress, failures and new approaches for TBI research. Nature Reviews Neurology2015;11:71‐2. ">Menon 2015</a>). Unfortunately, in this review, we only performed subgroup analysis according to GCS grade due to the lack of inclusion of more detailed data in the included trials. These heterogeneities might explain the dissociation seen in the effect of progesterone between animal models and these human trials. </p> <p>So far, all pharmacological interventions in TBI have failed, which led to discussion of the problematic neuroprotection end‐points in clinical trials (<a href="./references#CD008409-bbs2-0026" title="GultekinR , HuangS , ClavisiO , PattuwageL , KönigTC , GruenR . Pharmacological interventions in traumatic brain injury: can we rely on systematic reviews for evidence?. Injury2016;47:516‐24. ">Gultekin 2016</a>). It appears that the commonly used GOS and GOS‐E (Glasgow Outcome Scale‐extended), which measure global functioning after TBI, do not adequately reflect the patients' neurologic function, especially for specific deficits in behaviour, executive function, memory and emotion that may produce significant disabilities. This limitation can become even more evident when the scores are subjectively dichotomised into `unfavourable' and `favourable' outcomes (<a href="./references#CD008409-bbs2-0039" title="PoonW , VosP , MuresanuD , VesterJ , vonWildK , HombergV . Cerebrolysin Asian Pacific trial in acute brain injury and neurorecovery: design and methods. Journal of Neurotrauma2015;32:571–80. ">Poon 2015</a>; <a href="./references#CD008409-bbs2-0046" title="SteinDG . Embracing failure: what the Phase III progesterone studies can teach about TBI clinical trials. Brain Injury2015;29:1259‐72. ">Stein 2015</a>). </p> <p>Therefore, we consider that the different timescales of outcome measures, differing dosage of progesterone, and heterogeneity of participants, reduce our confidence in the conclusions of this review. </p> </section> </section> <section id="CD008409-sec-0079"> <h3 class="title" id="CD008409-sec-0079">Potential biases in the review process</h3> <p>We have attempted to minimise bias in this review and to be as inclusive as possible. We included five studies, but we expect that there may have been other trials that have been conducted that we were unable to identify. </p> <p>We excluded three studies that were not prospectively registered and published their reports after 2010 (<a href="./references#CD008409-bbs2-0007" title="AminmansourB , NikbakhtH , GhorbaniA , RezvaniM , RahmaniP , TorkashvandM . Comparison of the administration of progesterone versus progesterone and vitamin D in improvement of outcomes in patients with traumatic brain injury: a randomized clinical trial with placebo group. Advanced Biomedical Research2012;1:58. ">Aminmansour 2012</a>; <a href="./references#CD008409-bbs2-0006" title="AbokhabarH , AbouelelaA , MousaS . Impact of progesterone administration on outcome of patients with severe traumatic brain injury. Intensive Care Medicine. 2012. ">Abokhabar 2012</a>; <a href="./references#CD008409-bbs2-0008" title="MofidB , SoltaniZ , KhaksariM , ShahrokhiN , NakhaeeN , KaramouzianS . What are the progesterone‐induced changes of the outcome and the serum markers of injury, oxidant activity and inflammation in diffuse axonal injury patients?. International Immunopharmacology2016;32:103‐10. ">Mofid 2016</a>), in accordance with <a href="./references#CD008409-bbs2-0041" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning health care is not fit for purpose and must change. BMJ2015;350:h2463. ">Roberts 2015</a>. We consider that this will have reduced bias in the review process. </p> </section> <section id="CD008409-sec-0080"> <h3 class="title" id="CD008409-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>A series of preclinical studies and results of phase II RCTs indicated that progesterone might be an appropriate candidate for the treatment of people suffering from TBI (<a href="./references#CD008409-bbs2-0045" title="SteinDG . Progesterone exerts neuroprotective effects after brain injury. Brain Research Reviews2008;57(2):386‐97. ">Stein 2008</a>; <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>; <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>). However, this updated systematic review did not find evidence that progesterone could provide a beneficial clinical outcome in people with TBI. It is possible that this negative result could be due to some of the problems with trial design that we have discussed under <a href="#CD008409-sec-0075">Quality of the evidence</a>. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008409-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008409-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008409-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Five studies are included in this review." data-id="CD008409-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Five studies are included in this review. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008409-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008409-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008409-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo, Outcome 1 Mortality at the end of the follow‐up period." data-id="CD008409-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo, Outcome 1 Mortality at the end of the follow‐up period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008409-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo, Outcome 2 Death or severe disability (GOS1 to 3) at the end of the follow‐up period." data-id="CD008409-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo, Outcome 2 Death or severe disability (GOS1 to 3) at the end of the follow‐up period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008409-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis: severe TBI subgroup (GCS ≤ 8), Outcome 1 Mortality at the end of the follow‐up period." data-id="CD008409-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis: severe TBI subgroup (GCS ≤ 8), Outcome 1 Mortality at the end of the follow‐up period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008409-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis: severe TBI subgroup (GCS ≤ 8), Outcome 2 Death or severe disability (GOS1 to 3) at the end of the follow‐up period." data-id="CD008409-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis: severe TBI subgroup (GCS ≤ 8), Outcome 2 Death or severe disability (GOS1 to 3) at the end of the follow‐up period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008409-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adequate allocation concealment (sensitivity analysis), Outcome 1 Mortality at the end of the follow‐up period." data-id="CD008409-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Adequate allocation concealment (sensitivity analysis), Outcome 1 Mortality at the end of the follow‐up period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008409-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/urn:x-wiley:14651858:media:CD008409:CD008409-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_t/tCD008409-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adequate allocation concealment (sensitivity analysis), Outcome 2 Death or severe disability (GOS 1 to 3) at the end of the follow‐up period." data-id="CD008409-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Adequate allocation concealment (sensitivity analysis), Outcome 2 Death or severe disability (GOS 1 to 3) at the end of the follow‐up period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/media/CDSR/CD008409/image_n/nCD008409-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008409-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with no progesterone or placebo for traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acute TBI secondary to head injury </p> <p><b>Settings:</b> hospitals, intensive care units </p> <p><b>Intervention:</b> progesterone therapy </p> <p><b>Comparison:</b> no progesterone or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality at end of scheduled follow‐up</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>175 per 1000</b> </p> <p><b>(125 to 246)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> (0.65 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2376<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is no evidence of a reduction of mortality at the end of scheduled follow‐up as a result of progesterone therapy. Our confidence in this evidence is limited as we have assessed it as low quality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disability (unfavourable outcomes: death, vegetative state, severe disability; GOS 1‐3) at end of scheduled follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>533 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>522 per 1000</b> </p> <p><b>(474 to 565)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.98</b> (0.89 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2260</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There is no evidence of a difference in disability (unfavourable outcomes) at the end of scheduled follow‐up as a result of progesterone therapy. Our confidence in this evidence is somewhat limited as we have assessed it as moderate quality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intracranial pressure (ICP) within the treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In <a href="./references#CD008409-bbs2-0005" title="XiaoG , WeiJ , YanW , WangW , LuZ . Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Critical Care2008;12:R61. ">Xiao 2008</a>, ICP data were presented as mean values. In <a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>, ICP data were presented as the mean frequency of pressures exceeding threshold values. In <a href="./references#CD008409-bbs2-0001" title="SkolnickBE , MaasAI , NarayanRK , van derHoopRG , MacAllisterT , WardJD . A clinical trial of progesterone for severe traumatic brain injury. The New England Journal of Medicine2014;371:2467‐76. ">Skolnick 2014</a>, ICP data were presented as the population with increased ICP. We were therefore not able to perform meta‐analysis. There was no evidence that progesterone therapy has an effect on ICP. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood pressure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Throughout the three‐day infusion interval, there was no difference between the progesterone and placebo groups" (<a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body temperature</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Progesterone group experienced a lower increase in mean temperature than the control group" (<a href="./references#CD008409-bbs2-0002" title="WrightDW , KellermannAL , HertzbergVS , ClarkPL , FrankelM , GoldsteinFC . ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine2007;49:391‐402. ">Wright 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008409-bbs2-0003" title="WrightDW , YeattsSD , SilbergleitR , PaleschYY , HertzbergVS , FrankelM . Very early administration of progesterone for acute traumatic brain injury. The New England Journal of Medicine2014;371:2457‐66. ">Wright 2014</a> reported that phlebitis or thrombophlebitis was significantly more frequent in the progesterone group than in the placebo group (882 cases, RR 3.03; 95% CI, 1.96 to 4.66). The rates of other serious and non‐serious adverse events were similar in the 4 studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval;<b>GOS:</b> Glasgow Outcome Scale; <b>ICP:</b> intracranial pressure; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. We judged the overall risk of bias of two studies as high, and two studies as unclear. However, most data were from studies at low or unclear risk of bias, so we did <i>not</i> downgrade for risk of bias. </p> <p>2. Downgraded once for inconsistency (substantial heterogeneity: I² = 62%, P value 0.03) </p> <p>3. Downgraded once for inconsistency (the dosage, treatment routine and vehicles of progesterone varied across studies. Different time points were involved in the analysis of mortality and unfavourable outcomes). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/full#CD008409-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008409-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progesterone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at the end of the follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.65, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death or severe disability (GOS1 to 3) at the end of the follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progesterone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008409-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: severe TBI subgroup (GCS ≤ 8)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at the end of the follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 severe TBI subgroup (GCS ≤ 8）</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.60, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 moderate TBI subgroup (GCS 9 to 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.70, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death or severe disability (GOS1 to 3) at the end of the follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.78, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 severe TBI subgroup (GCS ≤ 8）</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 moderate TBI subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.34, 1.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: severe TBI subgroup (GCS ≤ 8)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008409-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adequate allocation concealment (sensitivity analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at the end of the follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.60, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death or severe disability (GOS 1 to 3) at the end of the follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adequate allocation concealment (sensitivity analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008409.pub4/references#CD008409-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008409.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008409-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008409-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008409-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008409-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD008409-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008409\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008409\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008409\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008409\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008409\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008409.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008409.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008409.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008409.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008409.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716559134"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008409.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716559138"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008409.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da2757d0d9379',t:'MTc0MDcxNjU1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 